BioCryst Pharmaceuticals’ (BCRX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report published on Tuesday,Benzinga reports. The brokerage currently has a $30.00 price objective on the biotechnology company’s stock.

BCRX has been the subject of several other reports. Needham & Company LLC raised their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Evercore ISI upped their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. JMP Securities reissued a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Finally, Barclays upped their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $8.28 on Tuesday. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $9.50. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -13.57 and a beta of 1.75. The business’s 50 day moving average price is $8.05 and its two-hundred day moving average price is $7.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same period in the prior year, the company posted $0.28 EPS. The business’s quarterly revenue was up 40.8% compared to the same quarter last year. Sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Mackenzie Financial Corp lifted its position in shares of BioCryst Pharmaceuticals by 190.7% in the 4th quarter. Mackenzie Financial Corp now owns 84,662 shares of the biotechnology company’s stock worth $637,000 after purchasing an additional 55,535 shares during the period. GF Fund Management CO. LTD. purchased a new stake in BioCryst Pharmaceuticals during the fourth quarter worth $33,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in BioCryst Pharmaceuticals by 3.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company’s stock valued at $3,016,000 after acquiring an additional 11,581 shares in the last quarter. Woodline Partners LP purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $3,385,000. Finally, Two Sigma Advisers LP increased its holdings in shares of BioCryst Pharmaceuticals by 14.6% in the 4th quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company’s stock valued at $18,799,000 after acquiring an additional 318,800 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.